insights_auto
Kodėl „M1RN34“ padidėjo 6,66%?
Įsigilintichevron_right
M1RN34:BVMF
Moderna Inc Bdr
75,39 BRL
arrow_upward
+6,66%(+4,71) 1 D.
11-09, 18:07:00 GMT−3 · BRL
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „M1RN34“ įžvalgos...
Atidaryti
71,17 BRL
Aukšta
77,25 BRL
Žema
69,90 BRL
Rinkos kapitalizacija
107,39 mlrd.
Vid. kiekis
160,63 tūkst.
Apimtis
153,67 tūkst.
52 sav. aukšta
77,25 BRL
52 sav. žema
6,02 BRL
Neapmokėtos akcijos
399,24 mln.
Darbuotojų skaičius
5 tūkst.
Atidaryti
71,17 BRL
Aukšta
77,25 BRL
Žema
69,90 BRL
Rinkos kapitalizacija
107,39 mlrd.
Vid. kiekis
160,63 tūkst.
Apimtis
153,67 tūkst.
52 sav. aukšta
77,25 BRL
52 sav. žema
6,02 BRL
Neapmokėtos akcijos
399,24 mln.
Darbuotojų skaičius
5 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Yahoo Finance
·
prieš 1 valandą
Is Moderna (MRNA) Priced For Too Much Sales Growth?
The Motley Fool
·
prieš 1 valandą
Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy
Yahoo Finance
·
prieš 2 valandas
Moderna (MRNA) Stock Fair Value Rises After Intismeran Data And Q3 Beat
Profilis
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine sold under the brand names Spikevax and Mnexspike, a respiratory syncytial virus vaccine sold under the brand name Mresvia, and an influenza vaccine sold under the brand name Mflusiva. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.
In May 2026, Time ranked Moderna first in their list of the World's Most Impactful Companies. Wikipedia
Apie „Moderna Inc Bdr“
Generalinis direktoriusStéphane Bancel
Darbuotojai4,7 tūkst.
Įkurtarugs. 2010
Pagrindinė būstinė-
SektoriusHealth Care
Pramonės sritis-
Svetainėmodernatx.com